Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sleep Disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    320 result(s) found for: Sleep Disorder. Displaying page 9 of 16.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2012-004132-33 Sponsor Protocol Number: D1050304 Start Date*: 2013-05-02
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features (Protocol No D1050304)
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006487-24 Sponsor Protocol Number: ADNorGC Start Date*: Information not available in EudraCT
    Sponsor Name:Helse Bergen HF
    Full Title: A registry-based, open-label, randomized study to investigate quality-of-life with Plenadren compared with Cortison in participants aged 16-80 with newly diagnosed primary adrenal insufficiency
    Medical condition: Primary adrenal insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10052381 Primary adrenal insufficiency PT
    Population Age: Adolescents, Under 18, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003888-59 Sponsor Protocol Number: C.2524.0493.01 Start Date*: 2014-03-17
    Sponsor Name:University of Amsterdam
    Full Title: ADHD: Medication or Meditation?
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004109-27 Sponsor Protocol Number: 2.12.05 Start Date*: 2006-03-24
    Sponsor Name:Neuropsychiatric clinic
    Full Title: A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies
    Medical condition: Parkinsons disease (PD)and dementia with Lewy bodies (DLB) are both common disease of the elderly. The majority of patients who survive for more than 10 years with PD eventually develope dementia ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020698-17 Sponsor Protocol Number: 2010_3 Start Date*: 2010-10-04
    Sponsor Name:Antwerp University Hospital : Department Respiratory Medicine
    Full Title: Study of the vascular wall with functional imaging in OSA patients.
    Medical condition: Obstructive sleep apnea (OSA) is a prevalent disorder and characterised by sleepiness during the daytime, fatigue and impairments of concentration. OSA can also lead to cardiovascular pathology due...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005282-22 Sponsor Protocol Number: 42847922MDD2001 Start Date*: 2017-10-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005200-15 Sponsor Protocol Number: 6096-022 Start Date*: 2012-05-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients with Major Depressive Disorder.
    Medical condition: depression
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10066555 Chronic depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2005-003745-14 Sponsor Protocol Number: D1448C00005 Start Date*: 2006-01-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-centre, Double-blind, Randomised Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Monothe...
    Medical condition: Maintenance treatment of patients with Major Depressive Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001482-17 Sponsor Protocol Number: F1D-MC-HGKQ(b) Start Date*: 2004-10-15
    Sponsor Name:Eli Lilly and Company
    Full Title: Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I disorder.
    Medical condition: Manic or Mixed Episodes Associated with Bipolar I Disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002140-24 Sponsor Protocol Number: CSC/Trazo-01/07 Start Date*: 2007-07-12
    Sponsor Name:CSC Pharmaceuticals Handels GmbH.
    Full Title: Open-label, Multicenter Clinical Study of Dose-dependent Efficacy and Safety of Trazodone Hydrochloride in Patients wirh Major Depressive Disorder ans Pain (TIPAD Study)
    Medical condition: Major Depression Disorder associated with painful physical symptoms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057840 Major depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001685-38 Sponsor Protocol Number: 2693-CL-0312 Start Date*: 2021-11-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering from Moderate to Severe Vasomotor Symptoms (H...
    Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) ES (Ongoing) IT (Completed) HU (Completed) FI (Completed) NL (Completed) NO (Completed) DE (Completed) PL (Completed) DK (Completed) BE (Completed) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005054-46 Sponsor Protocol Number: D1448C00011 Start Date*: 2006-03-17
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR...
    Medical condition: Generalised Anxiety Disorder (GAD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) ES (Completed) DK (Completed) DE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-002565-17 Sponsor Protocol Number: WODDOL Start Date*: 2021-12-02
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Multi-center study to evaluate virological efficacy, safety tolerability, drug exposure and patients’ reported outcomes over 48 weeks following randomization to 2-drug therapy with DTG/3TC FDC or c...
    Medical condition: HIV-1-infected adult women of >18 years of age, without previous virologic failure, currently receiving an effective (HIV-RNA < 50 copies/ml) triple-drug cART, containing tenofovir (TAF or TDF) in ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005055-18 Sponsor Protocol Number: D1448C00012 Start Date*: 2006-05-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-centre, Double-blind, Randomised-Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Monothe...
    Medical condition: Maintenance treatment of patients with Generalised Anxiety Disorder.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000256-33 Sponsor Protocol Number: Ra-P-OCD-01 Start Date*: 2019-06-27
    Sponsor Name:Uppsala University Hospital
    Full Title: A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement
    Medical condition: Obsessive-compulsive disorder (OCD) or Obsessive-compulsive behaviour (OCB) or psychotic disorder (PD) in which there is an indication of immune system involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10029898 Obsessive-compulsive disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001884-21 Sponsor Protocol Number: CCTU0251-ATP Start Date*: 2019-06-04
    Sponsor Name:Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge
    Full Title: A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant P2X7 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an inc...
    Medical condition: Major depressive disorder with an incomplete response to monoaminergic antidepressants and with biomarker profile indicative of inflammation
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-002423-36 Sponsor Protocol Number: S66832 Start Date*: 2023-05-30
    Sponsor Name:KU Leuven
    Full Title: Evaluation of oxytocin treatment in children with autism and intellectual disability
    Medical condition: Autism Spectrum Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10067989 Intellectual disability PT
    21.1 10037175 - Psychiatric disorders 10063844 Autism spectrum disorder PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000986-10 Sponsor Protocol Number: D1050296 Start Date*: 2011-12-14
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE PREVENTION OF RECURRENCE IN SUBJECTS WITH BIPOLAR I DISO...
    Medical condition: Bipolar disorder I depression
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000149-34 Sponsor Protocol Number: CR845-310302 Start Date*: 2023-01-17
    Sponsor Name:Cara Therapeutics, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Seve...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001668-31 Sponsor Protocol Number: CL3-16257-097 Start Date*: 2012-10-05
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation, in patients with stable coronary artery disease. A 6 to 12-mon...
    Medical condition: Stable coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SK (Completed) NL (Completed) ES (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 13:32:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA